ARS Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

ARS Pharmaceuticals

20/03/2025 13:31

ARS Pharmaceuticals Inc SPRY.OQ reported quarterly adjusted earnings of 49 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -7 cents.  The mean expectation of five analysts for the quarter was for a loss of 14 cents per share. Wall Street expected results to range from -31 cents to 28 cents per share.

Revenue was $86.58 million​; analysts expected $15.82 million.

ARS Pharmaceuticals Inc's reported EPS for the quarter was 49 cents​.

The company reported quarterly net income of $49.93 million.

ARS Pharmaceuticals Inc shares had risen by 10.4% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 5.1% in the last three months.​

In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The average consensus recommendation for the biotechnology & medical research peer group is also "strong buy"

Wall Street's median 12-month price target for ARS Pharmaceuticals Inc is $31.50

This summary was machine generated from LSEG data March 20 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
-0.14
0.49
Beat
Sep. 30 2024
-0.15
-0.20
Missed
Jun. 30 2024
-0.12
-0.13
Missed
Mar. 31 2024
-0.11
-0.11
Met